Summary of key metrics and trend context (USD thousands unless noted):
- Revenue: 59,366; YoY +0.5%; QoQ +0.5%
- Gross Profit: 59,366; Gross Margin: 100.0% (as reported)
- Research & Development Expenses: 33,524
- Selling, General & Administrative Expenses: 112,212
- Operating Expenses: 145,736
- Interest Expense: 181,516
- Depreciation & Amortization: (−123,000)
- EBITDA: (−29,885)
- Operating Income: (−86,370); Operating Margin: −1.45%
- Total Other Income/Expenses Net: 19,499
- Income Before Tax: (−265,000); Pretax Margin: −4.46%
- Net Income: (−167,000); Net Margin: −2.81%
- EPS: (−$0.0297); Weighted Avg Shares: 4.11 million
- Cash Flow: Net Income (−$264,899); Change in Working Capital (−$52,037); Net Cash from Operating Activities (−$148,895)
- Cash at End: $716; Cash at Beginning: $61,849; Free Cash Flow: (−$148,900)
- Balance Sheet Highlights: Total Assets $177,611; Total Liabilities $5,371,640; Stockholders’ Equity (−$5,194,029); Current Liabilities dominated by Other Current Liabilities ($4,548,272) and Short-Term Debt ($793,699)
- Liquidity Ratios: Current Ratio 0.0267; Quick Ratio 0.0267; Cash Ratio 0.000133
- Valuation Signals: P/S ~13.32; P/BV Negative; Enterprise Value Multiple −52.99 (reflecting negative equity)
- Notable Trend: Revenue and gross profit appear to be flat-to-up slightly YoY/QoQ, but operating losses and cash burn persist, driven by substantial interest expense and SG&A/R&D spend.
Note: All figures are USD and sourced from the QQ4 2024 disclosure and related four-quarter data. Management commentary from the earnings call is not provided in the data set; where possible, the analysis references disclosed figures and common biotech industry context.